Here’s a startling revelation: the way we’ve been monitoring lymphoma patients might be missing the mark. But what if a simple blood test could predict treatment outcomes more accurately than traditional imaging? That’s exactly what new research suggests about circulating tumor DNA (ctDNA). And this is the part most people miss—it’s not just about accuracy; it’s about revolutionizing personalized care for lymphoma patients.
Recent findings from a real-world analysis presented at the 2025 ASH Annual Meeting and Exposition reveal that ctDNA status at the end of treatment (EOT) is a powerful predictor of event-free survival (EFS) across various lymphoma subtypes. But here’s where it gets controversial: ctDNA outperformed PET-CT scans in detecting residual disease and predicting relapse, challenging the long-standing reliance on imaging in clinical practice. Could this shift the paradigm of how we monitor lymphoma?
The study, led by Natalie Galanina, MD, from UPMC Hillman Cancer Center, analyzed 1105 plasma samples from 144 lymphoma patients across 14 subtypes. The results were striking: patients with negative ctDNA minimal residual disease (MRD) at EOT had significantly longer EFS compared to those with positive ctDNA-MRD. For instance, the median EFS was not achieved in the ctDNA-MRD-negative group, while it was just 1.97 months in the positive group. This raises a critical question: Should ctDNA testing become the gold standard for lymphoma monitoring, or is it too early to replace PET-CT entirely?
Galanina highlighted that ctDNA kinetics provide real-time insights into treatment response, even predicting outcomes for patients undergoing CAR T-cell therapy. For example, patients who cleared ctDNA within 3 months post-CAR T-cell therapy achieved durable remission at 1 year. However, one patient relapsed after becoming ctDNA-negative, suggesting that single time-point measurements might not suffice. Is longitudinal ctDNA testing the future of relapse detection?
The study also found that early ctDNA clearance—as early as cycle 1 of treatment—was associated with improved EFS outcomes. This could have significant implications for therapy de-escalation, especially for older patients or those with comorbidities. But here’s the debate: If ctDNA clearance indicates a lower risk of relapse, should we reconsider aggressive treatment regimens for certain patients?
Interestingly, the data showed that 75% of PET-positive, ctDNA-MRD-negative patients did not progress, suggesting they might not need additional therapy. This finding challenges the current approach to managing PET-positive patients. Could ctDNA testing reduce overtreatment in lymphoma care?
In conclusion, ctDNA’s role as a prognostic tool is undeniable, but its integration into routine clinical practice sparks debate. While it offers unparalleled precision, questions remain about its optimal use, cost-effectiveness, and long-term impact on patient outcomes. What’s your take? Should ctDNA replace PET-CT, or should it complement existing methods? Share your thoughts in the comments—let’s keep the conversation going.
